RecruitingObesity

Efficacy and Safety of Attapulgite in Patients With Obesity: An Exploratory Clinical Trial

Eligible age

18–60 yrs

Accepts

All genders

Locations

0 states

Healthy volunteers

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

To explore the safety and efficacy of attapulgite in the treatment of obese individuals or overweight/obese individuals with type 2 diabetes.

Sponsor: Second Xiangya Hospital of Central South University

✓ Obese individuals:
✓ Aged 18-60 years, regardless of sex/gender
✓ BMI≥28.0kg/m2
✓ Overweight or obese individuals with type 2 diabetes:
✓ Aged 18-60 years, regardless of sex/gender
✓ BMI≥24.0kg/m2
✓ HbA1c ≥7.0% and ≤10.0% or the fasting blood glucose ≥7.0 mmol/l and ≤ 13.3 mmol/l at screening
✓ Stable diabetes treatment for at least 6 months or more

✕ Type 1 diabetes, monogenic diabetes, or diabetes due to pancreatic injury or other secondary diabetes
✕ Severe diabetic complications within three months before the study initiation, including severe hypoglycemia, diabetic ketoacidosis, or infections
✕ Use of weight-affecting products within the past three months or planned use during the study
✕ Weight fluctuation \>5 kg or \>10% within the past three months
✕ Obesity or overweight due to endocrine disorders (such as thyroid dysfunction or Cushing's syndrome)
✕ Uncontrolled hypertension, severe cardiac/hepatic/renal dysfunction
✕ History of gastrointestinal surgery (such as cholecystectomy) within the past year or non-gastrointestinal surgery within six months, or prior bariatric surgery
✕ Chronic gastrointestinal disorders (such as recurrent constipation, celiac disease, or food intolerances) or any condition impairing digestion/absorption function

Source: ClinicalTrials.gov · NCT07103382 · last updated 2025-09-05